Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer

Li, N; Bu, H; Liu, J; Zhu, J; Zhou, Q; Wang, L; Yin, R; Wu, X; Yao, S; Gu, K; Zhang, H; Li, G; Pan, H; Wu, Q; An, R; Yang, X; Zhu, Y; Wan, X; Duan, Wei; Xiong, J; Wang, Y; Wang, Q; Zou, J; Wu, LY

Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer

journal contribution

posted on 2024-07-31, 01:34 authored by N Li, H Bu, J Liu, J Zhu, Q Zhou, L Wang, R Yin, X Wu, S Yao, K Gu, H Zhang, G Li, H Pan, Q Wu, R An, X Yang, Y Zhu, X Wan, Wei DuanWei Duan, J Xiong, Y Wang, Q Wang, J Zou, LY Wu

Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer

History

Journal

Gynecologic Oncology

Volume

159

Pagination

159-159

ISSN

0090-8258

Language

en

Publication classification

E3.1 Extract of paper

Publisher

Elsevier BV

Publication URL

http://dx.doi.org/10.1016/j.ygyno.2020.05.229

Usage metrics

Keywords

Women's Health Ovarian Cancer Rare Diseases Orphan Drug Cancer 5.1 Pharmaceuticals 6.1 Pharmaceuticals

Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer

History

Journal

Volume

Pagination

ISSN

Language

Publication classification

Publisher

Publication URL

Usage metrics

Categories

Keywords

Licence

Exports